×
News Home

Do Traders Think CymaBay Therapeutics Inc (CBAY) Can Turn Around Wednesday?

Wednesday, October 05, 2022 01:30 PM | InvestorsObserver Analysts
Do Traders Think CymaBay Therapeutics Inc (CBAY) Can Turn Around Wednesday?

CymaBay Therapeutics Inc (CBAY) stock is down 3.64% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bullish
CymaBay Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CBAY!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CBAY Stock Today?

CymaBay Therapeutics Inc (CBAY) stock is trading at $3.44 as of 1:29 PM on Wednesday, Oct 5, a loss of -$0.12, or -3.24% from the previous closing price of $3.55. The stock has traded between $3.40 and $3.50 so far today. Volume today is 397,965 compared to average volume of 410,949.

More About CymaBay Therapeutics Inc

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta. Click Here to get the full Stock Report for CymaBay Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App